Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement

Larry Alphs, Cynthia Bossie, Lian Mao, Erin Lee, H Lynn Starr, Larry Alphs, Cynthia Bossie, Lian Mao, Erin Lee, H Lynn Starr

Abstract

Aim: Long-acting injectable antipsychotics (APs) are not well studied in recent-onset schizophrenia. This exploratory analysis of a study designed to reflect real-world schizophrenia, as defined by patients, interventions and outcomes, compared relative treatment effect between once-monthly paliperidone palmitate (PP) and daily oral APs in patients with recent-onset or chronic illness METHODS: This randomized, open-label, event monitoring board-blinded study compared treatment response in subjects with schizophrenia and a history of criminal justice system involvement following treatment with PP or oral APs for 15 months (ClinicalTrials.gov identifier, NCT01157351). Event-free probabilities were estimated using Kaplan-Meier method; hazard ratios (HRs) were estimated using Cox proportional hazard models. This subgroup analysis analysed data by disease duration (≤5 (recent-onset) or >5 years (chronic illness) since first psychiatric diagnosis).

Results: Seventy-seven subjects met the criteria for recent-onset illness; 365 for chronic illness. HRs (95% CI) for treatment failure for oral APs versus PP were 1.73 (0.87-3.45; P = 0.121) for recent-onset and 1.37 (1.02-1.85; P = 0.039) for chronic illness. Most common adverse events for PP versus oral APs were injection site pain (recent-onset, 26% vs. 0%; chronic, 17% vs. 0%), increased weight (14% vs. 6%; 12% vs. 6%), akathisia (14% vs. 9%; 10% vs. 7%), insomnia (12% vs. 17%; 18% vs. 10%) and anxiety (12% vs. 6%; 10% vs. 8%).

Conclusions: Although neither pre-planned nor adequately powered, the estimated HRs suggest that the relative advantage of PP over oral APs for reducing the risk for treatment failure may be greater in patients with recent-onset schizophrenia than in those with more chronic illness.

Keywords: disease duration; long-acting injectable; oral antipsychotic; paliperidone palmitate; schizophrenia.

© 2015 The Authors. Early Intervention in Psychiatry published by Wiley Publishing Asia Pty Ltd.

Figures

Figure 1
Figure 1
Study flow of subjects with recent‐onset or chronic illness in the PRIDE study. *Two subjects did not have data available for the duration of their illness and were not included.
Figure 2
Figure 2
Kaplan–Meier estimate of time to first treatment failure for subjects with (a) recent‐onset (≤5 years) and (b) chronic illness (>5 years). AP, antipsychotic; CI, confidence interval; HR, hazard ratio; PP, paliperidone palmitate.
Figure 3
Figure 3
Kaplan–Meier estimate of time to first psychiatric hospitalization or arrest/incarceration for subjects with (a) recent‐onset (≤5 years) and (b) chronic illness (>5 years). AP, antipsychotic; CI, confidence interval; HR, hazard ratio; PP, paliperidone palmitate.

References

    1. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996; 22: 201–222.
    1. McGlashan TH. A selective review of recent North American long‐term followup studies of schizophrenia. Schizophr Bull 1988; 14: 515–542.
    1. Mihalopoulos C, Harris M, Henry L, Harrigan S, McGorry P. Is early intervention in psychosis cost‐effective over the long term? Schizophr Bull 2009; 35: 909–918.
    1. Bertelsen M, Jeppesen P, Petersen L et al Five‐year follow‐up of a randomized multicenter trial of intensive early intervention vs. standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry 2008; 65: 762–771.
    1. Alonso J, Croudace T, Brown J et al Health‐related quality of life (HRQL) and continuous antipsychotic treatment: 3‐year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health 2009; 12: 536–543.
    1. Canuso CM, Bossie CA, Amatniek J, Turkoz I, Pandina G, Cornblatt B. Paliperidone extended‐release tablets in patients with recently diagnosed schizophrenia. Early Interv Psychiatry 2010; 4: 64–78.
    1. Lieberman J, Jody D, Geisler S et al Time course and biologic correlates of treatment response in first‐episode schizophrenia. Arch Gen Psychiatry 1993; 50: 369–376.
    1. Ceskova E, Prikryl R, Kasparek T, Ondrusová M. Psychopathology and treatment responsiveness of patients with first‐episode schizophrenia. Neuropsychiatr Dis Treat 2005; 1: 179–185.
    1. Gerretsen P, Plitman E, Rajji TK, Graff‐Guerrero A. The effects of aging on insight into illness in schizophrenia: a review. Int J Geriatr Psychiatry 2014; 29: 1145–1161.
    1. Quach PL, Mors O, Christensen TO et al Predictors of poor adherence to medication among patients with first‐episode schizophrenia‐spectrum disorder. Early Interv Psychiatry 2009; 3: 66–74.
    1. Kamali M, Kelly BD, Clarke M et al A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry 2006; 21: 29–33.
    1. Lamberti JS, Weisman RL. Persons with severe mental disorders in the criminal justice system: challenges and opportunities. Psychiatr Q 2004; 75: 151–164.
    1. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first‐episode schizophrenia. Am J Psychiatry 1992; 149: 1183–1188.
    1. Harrison G, Hopper K, Craig T et al Recovery from psychotic illness: a 15‐ and 25‐year international follow‐up study. Br J Psychiatry 2001; 178: 506–517.
    1. McGorry PD. Early intervention in psychotic disorders: beyond debate to solving problems. Br J Psychiatry Suppl 2005; 48: s108–110.
    1. Emsley R, Chiliza B, Asmal L, Mashile M, Fusar‐Poli P. Long‐acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry 2013; 7: 247–254.
    1. Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L. Comparison of treatment response in second‐episode versus first‐episode schizophrenia. J Clin Psychopharmacol 2013; 33: 80–83.
    1. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286–290.
    1. Valenstein M, Blow FC, Copeland LA et al Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255–264.
    1. Lang K, Meyers JL, Korn JR et al Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv 2010; 61: 1239–1247.
    1. Alphs L, Mao L, Rodriguez SC, Hulihan J, Starr HL. Design and rationale of the paliperidone palmitate research in demonstrating effectiveness (PRIDE) study: a novel comparative trial of once‐monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. J Clin Psychiatry 2014; 75: 1388–1393.
    1. Alphs L, Benson C, Cheshire‐Kenny K et al Real‐world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open‐label, review board‐blinded 15‐month study. J Clin Psychiatry 2015; 76: 554–561.
    1. Bossie CA, Fu DJ, Sliwa JK, Ma YW, Alphs L. Tolerability of initiation doses of once‐monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol 2011; 1: 111–124.
    1. Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L. Paliperidone palmitate versus oral risperidone and risperidone long‐acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol 2014; 29: 45–55.
    1. Sheehan DV, Lecrubier Y, Harnett Sheehan K et al The Mini‐International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10. J Clin Psychiatry 1998; 59: 22–33.
    1. Chue P, Emsley R. Long‐acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007; 21: 441–448.
    1. Macfadden W, Bossie CA, Turkoz I, Haskins JT. Risperidone long‐acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol 2010; 25: 75–82.
    1. Bartzokis G, Lu PH, Amar CP et al Long acting injection versus oral risperidone in first‐episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res 2011; 132: 35–41.
    1. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long‐acting injectable risperidone in the treatment of subjects with recent‐onset psychosis: a preliminary study. J Clin Psychopharmacol 2008; 28: 210–213.
    1. Barrio P, Batalla A, Castellvi P et al Effectiveness of long‐acting injectable risperidone versus oral antipsychotics in the treatment of recent‐onset schizophrenia: a case‐control study. Int Clin Psychopharmacol 2013; 28: 164–170.
    1. Ucok A, Saka MC, Bilici M. Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: an open‐label, single‐arm, flexible‐dose, 12‐months follow‐up study. Nord J Psychiatry 2015; 69: 426–432.
    1. Subotnik KL, Casaus LR, Ventura J et al Long‐acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first a randomized clinical trial. JAMA Psychiatry 2015; 72: 822–829. doi: .
    1. Morken G, Widen JH, Grawe RW. Non‐adherence to antipsychotic medication, relapse and rehospitalisation in recent‐onset schizophrenia. BMC Psychiatry 2008; 8: 32.
    1. Subotnik KL, Nuechterlein KH, Ventura J et al Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168: 286–292.
    1. Parellada E, Andrezina R, Milanova V et al Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long‐acting injectable. J Psychopharmacol 2005; 19: 5–14.
    1. Kelly DL, Conley RR, Carpenter WT. First‐episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005; 65: 1113–1138.
    1. Pandina GJ, Lindenmayer JP, Lull J et al A randomized, placebo‐controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010; 30: 235–244.
    1. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time‐to‐relapse in patients with schizophrenia: a randomized, double‐blind, placebo‐controlled study. Schizophr Res 2010; 116: 107–117.
    1. Gopal S, Hough DW, Xu H et al Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double‐blind, placebo‐controlled, dose‐response study. Int Clin Psychopharmacol 2010; 25: 247–256.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera